Synova
Harry Fitzpatrick is currently working as an Investment Executive in the Health & Life Sciences Investment Team at Synova since November 2021. Prior to this, Harry worked as an Origination Analyst in the Health & Life Sciences division at Goldman Sachs. Before that, Harry was a Trader in Equity derivatives at Goldman Sachs. Harry started their career at Goldman Sachs as a Securities Division Spring Intern in 2018 and later worked as a Securities Division Summer Analyst in 2019. Harry holds a MChem degree in Chemistry from the University of Oxford, where they attended from 2016 to 2020.
Synova
Synova is recognised across the industry as one of Europe’s most innovative growth investors, generating market-leading returns from investing in companies typically valued at between £20m and £250m. Synova is investing capital across the full mid-market spectrum from its £875m fifth fund, raised in 2022, which includes a dedicated £250m pool of capital, #Chrysalis, to support smaller growth companies. We work across a handful of core sectors where we have deep investment and operational expertise. The Synova model is focused on using this knowledge to help our partners outperform. Time and again we’ve helped companies achieve more – hitting ambitious targets by enhancing their capabilities. We work as one team across the whole business, giving companies access to deep pools of talent within Synova to help drive accelerated growth. We help entrepreneurs achieve their vision. We provide expertise, coupled with ambition. We are true partners for growth.